ASKA Pharmaceutical Holdings Co.,Ltd.
Formulation of Long-Term Vision “ASKA VISION 2035” and Medium-Term Management Plan 2028
Asuka Pharmaceutical Holdings has formulated the long-term vision "ASKA VISION 2035" looking ahead to 2035 and the "Medium-Term Management Plan 2028" for the three years starting fiscal 2026, targeting net sales of 85 billion yen and an operating income margin of 10%.
Key Figures
- Net sales target: 85 billion yen (Fiscal 2028)
- Operating income margin target: 10% (Fiscal 2028)
- ROE target: 10% (Fiscal 2028)
AI要約
Long-Term Vision "ASKA VISION 2035"
Asuka Pharmaceutical Holdings has formulated the long-term vision "ASKA VISION 2035" looking ahead to 2035, aiming for sustainable growth and social contribution. Leveraging its foundation in the prescription pharmaceutical business primarily focused on obstetrics and gynecology, the company will strengthen drug discovery research, expand overseas operations, and develop animal health, diagnostic, and around-the-pill businesses. It clarifies its purpose, vision, and mission to provide value to stakeholders.
Overview of the Medium-Term Management Plan 2028
The "Medium-Term Management Plan 2028," covering fiscal years 2026 through 2028, represents the first phase of execution toward realizing the long-term vision. The financial targets include net sales of 85 billion yen, operating income margin of 10%, ROE of 10%, and total payout ratio of 40%. Business strategies focus on strengthening the prescription pharmaceutical business, expanding the business portfolio, and advancing overseas operations. Financial strategies emphasize optimizing cash allocation and considering agile share buybacks. To strengthen management foundations, the company will promote next-generation talent development, ESG initiatives, and digital transformation (DX).
